Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | CTSK | P43235 | 3/20 | 0.52 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | NPY4R | P50391 | 6/20 | 0.43 |
| ▸ | NPY1R | P25929 | 4/20 | 0.43 |
| ▸ | NPY2R | P49146 | 3/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 3/20 | 0.43 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Antipain SCHEMBL23132673 | 1.00 | SMN1; SMN2 (0.74) | SMN1; SMN2CTSKCTSBNPY4RNPY1R | |
| Antipain SCHEMBL18328611 | 1.00 | SMN1; SMN2 (0.74) | SMN1; SMN2CTSKCTSBNPY4RNPY1R | |
| Antipain SCHEMBL14038024 | 1.00 | SMN1; SMN2 (0.74) | SMN1; SMN2CTSKCTSBNPY4RNPY1R | |
| Antipain SCHEMBL3280675 | 1.00 | SMN1; SMN2 (0.74) | SMN1; SMN2CTSKCTSBNPY4RNPY1R | |
| Antipain SCHEMBL5966873 | 1.00 | SMN1; SMN2 (0.74) | SMN1; SMN2CTSKCTSBNPY4RNPY1R | |
| SCHEMBL26807763 | 0.97 | SMN1; SMN2 (0.69) | SMN1; SMN2CTSKCTSBNPY4RNPY1R | |
| SCHEMBL17364033 | 0.97 | SMN1; SMN2 (0.69) | SMN1; SMN2CTSKCTSBNPY4RNPY1R | |
| SCHEMBL16328962 | 0.93 | SMN1; SMN2 (0.65) | SMN1; SMN2CTSKCTSBNPY4RNPY1R | |
| SCHEMBL17364037 | 0.93 | SMN1; SMN2 (0.64) | SMN1; SMN2CTSKNPY4RNPY1RNPY2R | |
| SCHEMBL17364024 | 0.93 | SMN1; SMN2 (0.64) | SMN1; SMN2CTSKNPY4RNPY1RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1390 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137838-A1 | DEPOTS AND ENCASEMENT STRUCTURES FOR IMPLANTABLE DEVICES | ELUTIA MED LLC (US) | 2026-05-21 | — | — | US | claimed |
| EP-4673125-A1 | R-MDMA FOR TREATMENT OF PAIN | Mind Medicine, Inc. (US) | 2026-01-07 | — | — | EP | claimed |
| US-12514958-B2 | Depots and encasement structures for implantable devices | ELUTIA MED LLC (US) | 2026-01-06 | — | — | US | claimed |
| US-20250375420-A1 | COMPOSITIONS AND USES OF PSILOCYBIN AND PSILOCIN | ZYLORION HEALTH INC (CA) | 2025-12-11 | — | — | US | claimed |
| EP-3866826-B1 | ANTIMICROBIAL PEPTIDES AND METHODS OF USING THE SAME | RIPTIDE BIOSCIENCE INC (US) | 2025-12-10 | — | — | EP | claimed |
| US-20250360076-A1 | COMPOSITIONS CONTAINING PLANT MUCILAGE | PHAM PETER (US) | 2025-11-27 | — | — | US | claimed |
| EP-4652199-A1 | ANTI-CD19 BINDING AGENTS FOR THE TREATMENT AND PREVENTION OF IMMUNE MEDIATED NECROTIZING MYOPATHY | Viela Bio, Inc. (US) | 2025-11-26 | — | — | EP | claimed |
| EP-4640276-A2 | INHIBITOR OF MNK FOR THE TREATMENT OF NEUROPATHIC PAIN | Board Of Regents, The University Of Texas System (US) | 2025-10-29 | — | — | EP | claimed |
| US-20250281579-A1 | Methods and Compositions for Oral Administration of Proteins | ORAMED PHARMACEUTICALS INC (IL) | 2025-09-11 | — | — | US | claimed |
| US-12377041-B2 | Compositions containing plant mucilage | PHAM PETER (US) | 2025-08-05 | — | — | US | claimed |
| US-20220160839-A1 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | ORAMED PHARMACEUTICALS, INC. (IL) | 2022-05-26 | — | — | US | claimed |
| US-11324772-B2 | Periodontal gel composition and method of use | PRUDENTIX LTD. (IL) | 2022-05-10 | — | — | US | claimed |
| WO-2022072504-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF VIRAL DISEASES | HEALION BIO, INC. (US) | 2022-04-07 | — | — | WO | claimed |
| EP-3972593-A1 | INHIBITOR OF MNK FOR THE TREATMENT OF NEUROPATHIC PAIN | Board of Regents, The University of Texas System (US) | 2022-03-30 | — | — | EP | claimed |
| CN-114196662-A | Preserving fluid of glutamate decarboxylase | 陈锦 | 2022-03-18 | — | — | CN | claimed |
| US-11266712-B2 | Antimicrobial peptides and methods of using the same | Riptide Bioscience, Inc. (US) | 2022-03-08 | — | — | US | claimed |
| WO-2022040206-A1 | DEPOTS AND ENCASEMENT STRUCTURES FOR IMPLANTABLE DEVICES | AZIYO MED, LLC (US) | 2022-02-24 | — | — | WO | claimed |
| US-20220047777-A1 | DEPOTS AND ENCASEMENT STRUCTURES FOR IMPLANTABLE DEVICES | AZIYO MED, LLC (US) | 2022-02-17 | — | — | US | claimed |
| EP-3946054-A1 | COMPOSITIONS, METHODS AND SYSTEMS FOR PROTEIN CORONA ANALYSIS FROM BIOFLUIDS AND USES THEREOF | Seer, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| EP-2272565-A2 | Prevention of thrombus formation and/or stabilization | CSL Behring GmbH (DE) | 2011-01-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260137838-A1 | DEPOTS AND ENCASEMENT STRUCTURES FOR IMPLANTABLE DEVICES | MMP1, BMP2, BMP6 | SMN1; SMN2 1664/4885CTSK 1470/4885CTSB 1127/4885 |
| US-20250375420-A1 | COMPOSITIONS AND USES OF PSILOCYBIN AND PSILOCIN | BDNF, NGF, PYGB | SMN1; SMN2 338/4885CTSK 1187/4885CTSB 91/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.